RA Capital Management

Activity from announced rounds

Activity in this selectionApr 30, 2026 · Apr 1, 2026

RA Capital Management founds, funds and scales companies in healthcare and planetary health, combining scientific research with capital from seed through public-market financings.

Its TechAtlas research platform informs investment decisions through detailed scientific and market analysis. Raven, its healthcare incubator, works on originating and co-creating companies, giving researchers a route from a scientific idea to a funded business.

Blackbird provides a clinical development accelerator alongside the investment platform. These capabilities are relevant for founders who need to design a development programme and reach clinical milestones, as well as finance laboratory or commercial work.

Sources
Rounds participated in
2
Confirmed lead rounds
—
2 roles undisclosed
New companies
2
First participation on record · 0 follow-on
Funding in participating rounds
$183M
2 disclosed · full round size, not this investor’s share

By stage

Series C+2

By primary sector

Biotech2

By country

Denmark1
United States1

Rounds

2 in this selection
Terremoto Biosciences

Develops highly targeted, small molecule medicines for cancer and rare diseases

$108MSeries C
Role not disclosed
Adcendo

Adcendo develops antibody-drug conjugates that deliver cancer drugs to tumor-associated targets, with clinical programs in solid tumors and soft tissue sarcoma.

$75MSeries C
Role not disclosed